Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Interaction of Enavogliflozin with Gemigliptin and Metformin in Healthy Volunteers
NCT05500898Phase 1Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of enavogliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Steady State for DWP16001, Area Under the Curve Over Dosing Interval at Steady State for DWP16001 and 2 more. Status: unknown.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05500898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05500898.